AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice

CME Available: https://auau.auanet.org/node/43029

At the conclusion of this activity, participants will be able to:

1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer

2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation

3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer

4. Discern the different prognostic endpoints provided by various genomic tests

5. Recognize candidates for, and implications of, germline testing for prostate cancer.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.